Livagen vs TUDCA
A side-by-side research comparison of Livagen and TUDCA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Livagen | TUDCA |
|---|---|---|
| Full name | Livagen (Lys-Glu-Asp-Ala Liver/Lymphocyte Bioregulator) | Tauroursodeoxycholic Acid |
| Category | Detox & Antioxidant | Detox & Antioxidant |
| Status | Research compound (peptide bioregulator) | OTC supplement / Investigational |
| Mechanism | As a signal peptide (Lys-Glu-Asp-Ala), it is proposed to decondense chromatin (heterochromatin) in lymphocytes and regulate gene expression in hepatic tissue, supporting liver function and cellular activity. | Acts as a chemical chaperone that reduces endoplasmic reticulum (ER) stress, inhibits apoptosis, protects mitochondria, improves bile flow and solubility, and provides neuroprotective and cytoprotective effects. |
| Molecular weight | ~460 Da | 571.81 Da |
| Half-life | Short (peptide) | Variable (enterohepatic recirculation) |
| Bioavailability | Oral (encapsulated) or subcutaneous | Moderate oral |
| Typical dose | ~1-2 capsules/day or short injectable courses | 250-500 mg per day |
| Frequency | Once daily | 1-2x daily |
| Route | Oral capsule or subcutaneous | Oral capsule |
Livagen reported benefits
- Liver function support
- Lymphocyte chromatin activation (proposed)
- Detox/antioxidant support
- Short course-based protocol
TUDCA reported benefits
- Liver protection and enzyme normalization
- Improved bile flow
- Reduced ER stress
- Mitochondrial protection
- Neuroprotective potential
- Gut barrier support
Related comparisons
Research and educational reference only. Not medical advice.